Nebulized hypertonic saline via positive expiratory pressure versus via jet nebulizer in patients with severe cystic fibrosis

Respiratory Care

Volumn 56, Issue 6, 2011, Pages 771-775

  O'Connell, Oisin J ^a   O'Farrell, Carmel ^a   Harrison, Mike J ^a   Eustace, Joseph A ^a   Henry, Michael T ^a   Plant, Barry J ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Antibiotics; CF; Cystic fibrosis; Hypertonic saline; Nebulizer; Pep; Positive expiratory pressure

Indexed keywords

ANTIBIOTIC AGENT; SALBUTAMOL; SODIUM CHLORIDE;

ADULT; ARTICLE; CASE REPORT; CHEST TIGHTNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG TOLERABILITY; FEMALE; HUMAN; JET NEBULIZER; LUNG INFECTION; NEBULIZER; POSITIVE EXPIRATORY PRESSURE NEBULIZER; PROSPECTIVE STUDY; QUESTIONNAIRE; SORE THROAT; TASTE DISORDER;

ADMINISTRATION, INHALATION; ADULT; ALBUTEROL; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; CYSTIC FIBROSIS; FEMALE; HUMANS; NEBULIZERS AND VAPORIZERS; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 79960690642     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.00866     Document Type: Article

References (24)

1. Cashman SM, Patino A, Delgado MG, Byrne L, Denham B, De Arce M. The Irish cystic fibrosis database. J Med Genet 1995;32(12):972-975.
2. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003;361(9358):681-689.
3. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999;79(Suppl 1):S23-S45.
4. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis. Cell 1998;95(7):1005-1015.
5. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Bye PT, et al. A controlled trial of long term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-240.
6. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354(3):241-250.
7. Mahlmeister M, Fink JB, Hoffman G, Fifer LF. Positive-expiratorypressure mask therapy: theoretical and practical considerations and a review of the literature. Respir Care 1991;36(11):1218-1229.
8. Klausen NO, Andersen JB. A new mode of administration of nebulized bronchodilators in severe bronchospasm. Eur J Respir Dis Suppl 1982;197:97-100.
9. Rodwell LT, Anderson SD. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 1996;21(5):282-289.
10. Welsh M, Ramsey BW, Accurso F, Cutting CR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The molecular and metabolic basis of inherited disease, 8th edition. New York: McGraw-Hill; 2001:5121-5188.
11. American Association for Respiratory Care clinical practice guideline: use of positive airway pressure adjuncts to bronchial hygiene therapy. Respir Care 1993;38(5):516-521.
12. Fahy JV, Wong HH, Geppetti P, Reis JM, Harris SC, Maclean DB, et al. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995;152(3):879-884.
13. Newman SP, Pavia D, Garland N, Clarke SW. Effects of various inhalation modes on the deposition of radioactive pressurised aerosols. Eur J Respir Dis 1982;63(119):57-65.
14. Andersen JB, Qvist J, Kann T. Recruiting collapsed lung through collateral channels with positive end-expiratory pressure. Scand J Respir Dis 1979;(60):260-266.
15. Meduri GU, Cook TR, Turner RE, Cohen M, Leeper KV. Noninvasive positive pressure ventilation in status asthmaticus. Chest 1996; 110(3):767-774.
16. Fauroux B, Itti E, Pigeot J, Isabey D, Meignan M, Ferry G, et al. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am J Respir Crit Care Med 2000;162(6):2265-2271.
17. Chan HK, Eberl S, Daviskas E, Constable C, Young I. Changes in lung deposition of aerosols due to hygroscopic growth: a fast SPECT study. J Aerosol Med 2002;15(3):307-311.
18. Laube BL, Gellar DE, Lin TC, Dalby RN, Diner-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care 2005;50(11):1438-1444.
19. Sant'Ambrogio G, Widdicombe J. Reflexes from airway rapidly adapting receptors. Respir Physiol 2001;125(1-2):33-45.
20. Rogers D. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1176-1193.
21. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bye PT, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52(10):900-903.
22. Ziment I. Respiratory pharmacology and therapeutics. Philadelphia: WB Saunders; 1978:60-104.
23. Bergsson G, Reeves E, McNally P, Chotirmall SH, Greene CM, Greally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol 2009;183(1):543-551.
24. Havasi V, Hurst CO, Briles TC, Yang F, Bains DG, Hassett DJ, Sorscher E. Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros 2008;7(4):267-269.